Rhinorrhea, cough and fatigue in patients taking sitagliptin.
Sitagliptin is a dipeptidyl peptidase-4 (DPP IV, CD26) inhibitor indicated for treatment of Type II diabetes as a second line therapy after metformin. We report fifteen sitagliptin intolerant patients who developed anterior and posterior rhinorrhea, cough, dyspnea, and fatigue. Symptoms typically developed within 1 to 8 weeks of starting, and resolved within 1 week of stopping the drug. Peak expiratory flow rates increased 34% in 8 patients who stopped sitagliptin. Similar changes were found in 4 out of 5 persons who had confirmatory readministration. Chart review identified 17 patients who tolerated sitagliptin and had no symptomatic changes. The sitagliptin intolerant group had higher rates of clinically diagnosed allergic rhinitis (15/15 vs. 6/18; p = 0.00005), Fisher's Exact test) and angiotensin converting enzyme inhibitor - induced cough (6/13 vs. 1/18; p = 0.012). Nasal and inhaled glucocorticoids may control the underlying allergic inflammation and abrogate this new sitagliptin - induced pharmacological syndrome. Potential mucosal and central nervous system mechanisms include disruption of neuropeptides and/or cytokines that rely on DPP IV for activation or inactivation, and T cell dysfunction.
Baraniuk
James N
JN
Department of Family Medicine, Quillen College of Medicine, East Tennessee State University, McMinnville, TN, USA. drmjamieson@gmail.com.
Jamieson
Mary J
MJ
Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):487-98
19748066
J Rheumatol. 2002 Sep;29(9):1858-66
12233879
Curr Allergy Asthma Rep. 2009 Mar;9(2):149-52
19210905
J Allergy Clin Immunol. 2008 Feb;121(2 Suppl):S398-401; quiz S419
18241690
Am J Respir Cell Mol Biol. 1994 Aug;11(2):173-80
8049077
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006739
18425967
Ann Intern Med. 1992 Aug 1;117(3):234-42
1616218
Biochemistry. 2003 Jan 28;42(3):694-701
12534281
BMJ. 2009 May 22;338:b1668
19465464
Hypertension. 2010 Feb;55(2):214-20
20065150
Chest. 2006 Jan;129(1 Suppl):169S-173S
16428706
Cardiol Rev. 2007 Nov-Dec;15(6):316-23
18090068
Eur Respir J. 2008 Jan;31(1):143-78
18166595
J Clin Epidemiol. 2007 Jun;60(6):547-53
17493508
J Allergy Clin Immunol. 2007 Aug;120(2):403-8
17531305
Adv Exp Med Biol. 2006;575:223-9
16700526
Curr Allergy Asthma Rep. 2007 May;7(2):100-4
17437679
J Clin Immunol. 2007 Jul;27(4):430-7
17525828
J Appl Physiol (1985). 1992 Nov;73(5):1867-72
1282125
Am J Respir Crit Care Med. 2005 Jan 1;171(1):5-11
15477496
Int Immunol. 1999 Mar;11(3):417-26
10221653
Handb Exp Pharmacol. 2009;(187):241-62
18825344
Respir Physiol Neurobiol. 2006 Jul 28;152(3):340-8
16326149
Peptides. 2004 Mar;25(3):521-5
15134871
Curr Top Med Chem. 2007;7(6):621-35
17352682
Clin Exp Rheumatol. 2001 Nov-Dec;19(6):673-80
11791639
Diabetologia. 2005 Apr;48(4):616-20
15770466
J Appl Physiol (1985). 1992 Nov;73(5):2069-73
1474087
Vasc Health Risk Manag. 2008;4(4):753-68
19065993
J Immunol. 2001 Dec 15;167(12):6745-55
11739489
Eur Arch Psychiatry Clin Neurosci. 2000;250(2):86-92
10853924
Am J Respir Cell Mol Biol. 1993 Nov;9(5):557-67
8217197
Clin Allergy Immunol. 2007;19:35-53
17153006
Biol Chem. 2002 Jul-Aug;383(7-8):1133-8
12437097
Bioorg Med Chem. 2003 Jan 17;11(2):207-15
12470715
Prim Care Respir J. 2009 Dec;18(4):250-7
19513495
Respiration. 2008;75(1):89-97
17637510
J Hum Hypertens. 2005 Oct;19(10):793-9
15951740
Naunyn Schmiedebergs Arch Pharmacol. 1996 Nov;354(5):662-9
8938667
Regul Pept. 2002 Jun 15;106(1-3):71-9
12047913
Schweiz Med Wochenschr. 2000;Suppl 125:99S-101S
11141955
Science. 2007 Sep 28;317(5846):1881-6
17901324
Eur Arch Otorhinolaryngol. 1995;252(8):465-8
8719587
Horm Metab Res. 2008 Dec;40(12):892-5
18726829
J Allergy Clin Immunol. 2009 Sep;124(3):447-53
19647861
Eur Arch Otorhinolaryngol. 1995;252(2):83-5
7541210
FASEB J. 2002 Jul;16(9):1132-4
12039843